Remove Books Remove Documentation Remove FDA
article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Karst The FDA Reduction-in-Force (Termination)or RIF(T)announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIFd. As folks steeped in the world of generic drugs And Hatch-Waxman know, theres a lot that happens before FDA can take action on an ANDA.

FDA 144
article thumbnail

New Lawsuit Challenges FDA’s Authority to Compel Patent Certifications

The FDA Law Blog

Koblitz — For years , FDA has been wrestling with questions about what patents should be listed in the Orange Book, but, as we have reported, FDA has made little to no progress on addressing those questions. One of those pressing questions that remains unanswered involves the listing of REMS patents in the Orange Book.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

According to the legal documents , the plaintiffs accused the companies of “violating federal antitrust laws, alleging “per se” and “rule of reason” violations”. Gilenya is an oral medication for multiple sclerosis. Fighting Entresto generics.

article thumbnail

Bluebird trumpets long-term data from beta-thalassaemia gene therapy

pharmaphorum

In the US, Zinteglo has hit a speed-bump with the FDA, which is asking for more information about production facilities before a review of clinical data can begin. In England, cost-effectiveness body NICE is reviewing Zinteglo and is due to publish draft document early in the new year. discount rate used by the Treasury. “We

article thumbnail

6 common patient questions about insulin biosimilars

The Checkup by Singlecare

Yes, as of March 2020 , insulin is considered a biologic product by the FDA. Regulatory bodies such as the FDA conduct thorough tests to confirm that they meet safety, purity, and potency standards. The FDA Purple Book database can be a good resource to determine whether a biologic drug is interchangeable.

FDA 52
article thumbnail

How a new investment is powering a revolution in clinical trial operations

pharmaphorum

Unfortunately, he continued, “the clinical trial industry is stuck in the financial equivalent of writing cheques to people and taking your cheque book to the bank to update your balance.”. When I first started working in clinical trials, people were just moving from paper documentation to EDCs,” Peleg says.

article thumbnail

2022 ISPE Aseptic Conference: Regulatory Panel Discusses ATMPs, Data Integrity, Inspections, & More

ISPE

FDA/CBER/OMPT/OCBQ. And I'd like to make industry aware of a PIC/S document that's intended to guide inspectors on good data governance practices. Director, Office of Pharmaceutical Quality Operations. 2022 PIC/S Chair, Sr. Corporate Regulatory Compliance & Enforcement Advisor. Rick Friedman. Brooke Higgins. Robert Sausville.

FDA 52